Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 10 mg Commercial Tablet (Test) to the 10 mg Clinical Tablet (Reference)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Idalopirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 10 Nov 2016 Planned primary completion date changed from Dec 2016 to Sep 2016.
- 10 Nov 2016 Status changed from discontinued to withdrawn prior to enrolment.
- 17 Oct 2016 Status changed from recruiting to discontinued based on new efficacy data from another study.